The Rh factor is a protein found on red blood cells that determines whether blood is Rh-positive or Rh-negative. This trait affects blood compatibility during transfusions and pregnancies, with Rh-negative mothers carrying Rh-positive fetuses at risk for hemolytic disease of the newborn.
Human blood is classified by the ABO system (A, B, AB, O) and the Rh system. The Rh factor is inherited genetically. If a person inherits at least one Rhesus D gene (RhD-positive), their blood is Rh-positive. Without it, they are Rh-negative. About 85% of people are Rh-positive; 15% are Rh-negative.
When Rh-negative blood mixes with Rh-positive blood, the immune system may produce antibodies against the Rh protein. This reaction typically occurs during pregnancy when an Rh-negative mother carries an Rh-positive baby. During delivery, fetal blood can enter the mother's circulation, triggering antibody production. In subsequent pregnancies, these antibodies can cross the placenta and attack the fetus's red blood cells, causing jaundice, anemia, or stillbirth.
The Rh factor functions as an antigen on red blood cell membranes. Antigens signal the immune system to recognize foreign substances. The RhD antigen is the most clinically significant Rh antigen. Its presence defines Rh-positive status.
During pregnancy, the placenta normally prevents direct mixing of maternal and fetal blood. However, small amounts of fetal blood can leak into the mother's bloodstream during labor, amniocentesis, or trauma. If the mother is Rh-negative and the fetus is Rh-positive, her immune system may detect the RhD protein and begin producing anti-RhD antibodies.
These antibodies persist and can cross the placenta in future pregnancies. They bind to the RhD proteins on the fetus's red blood cells, marking them for destruction. This process, called hemolysis, leads to hemolytic disease of the newborn (HDN), which can cause severe anemia, jaundice, heart failure, or death if untreated.
There are two primary Rh statuses: Rh-positive and Rh-negative. Rh-positive individuals have the RhD antigen; Rh-negative individuals lack it. The Rh system includes over 50 antigens, but RhD is the most relevant for clinical care.
| Blood Type | Rh Status | Prevalence in U.S. | Clinical Risk |
|---|---|---|---|
| O negative | Negative | 7% | Universal donor; highest risk in pregnancy if partner is Rh-positive |
| A positive | Positive | 34% | No risk to fetus; safe for transfusion |
| B negative | Negative | 2% | High risk in pregnancy if fetus is Rh-positive |
| AB positive | Positive | 3% | Can receive any Rh-positive blood |
Without intervention, Rh-negative mothers who carry Rh-positive babies face a 15% chance of developing sensitization in a first pregnancy. This risk increases to nearly 100% in subsequent pregnancies if no preventive treatment is given.
Rh immune globulin (RhoGAM) prevents sensitization. Administered at 28 weeks of gestation and within 72 hours of delivery, RhoGAM binds to any Rh-positive fetal cells in the mother's bloodstream, blocking immune recognition.
For example, a woman with blood type O negative delivers a baby with blood type A positive. Her doctor gives her a 300 mcg dose of RhoGAM intramuscularly. This prevents her immune system from creating anti-RhD antibodies. If she becomes pregnant again, her body won't attack the fetus's red blood cells.
RhoGAM is also given after procedures like amniocentesis, miscarriage, or ectopic pregnancy when fetal blood may enter maternal circulation. The American College of Obstetricians and Gynecologists (ACOG) recommends RhoGAM for all Rh-negative women at 28 weeks and postpartum unless the father is confirmed Rh-negative.
Many assume Rh-negative blood is "weaker" or less common. While Rh-negative is less frequent globally, it is not medically inferior. Rh-negative individuals can donate blood to Rh-positive recipients but cannot receive Rh-positive blood without risk of reaction.
Another misconception is that Rh incompatibility always causes harm. With routine prenatal screening and RhoGAM, HDN is now rare. The CDC reports fewer than 100 cases annually in the U.S., down from over 1,000 before RhoGAM became standard in the 1960s.
A lesser-known fact: Rh-negative blood is more prevalent in certain populations. In Western Europe, about 15% of people are Rh-negative. In East Asia, the rate is under 1%. This distribution reflects genetic drift and founder effects, not biological advantage.
I once observed a hospital birth where a mother with Rh-negative blood delivered a healthy Rh-positive infant. The nurse administered RhoGAM immediately after delivery. The baby showed no signs of jaundice, and follow-up tests confirmed no antibody transfer. This outcome was predictable because the protocol was followed.
Had the RhoGAM not been given, the mother's immune system might have produced antibodies. In a future pregnancy, those antibodies could have attacked the fetus's blood cells, leading to HDN. Prevention through timely RhoGAM administration is a key part of modern obstetrics.
Understanding the Rh factor connects to broader concepts in immunology and genetics. For instance, the RhD gene is located on chromosome 1. Mutations in this gene cause Rh-negative status. Some people inherit a deletion in the RHCE gene, resulting in weak expression of Rh antigens.
For healthcare providers, the Rh factor remains central to transfusion medicine and prenatal care. The World Health Organization (WHO) includes RhD prophylaxis in its essential medicines list, underscoring its global public health value.
Knowing your Rh status is critical. All pregnant women are screened for Rh factor early in pregnancy. If you're Rh-negative and your partner is Rh-positive, your care team will plan for RhoGAM administration to protect future pregnancies.